FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280579758> ?p ?o ?g. }

• W4280579758 endingPage "936" @default.
• W4280579758 startingPage "926" @default.
• W4280579758 abstract "Background: Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid malignancy that is associated with poor prognosis. Current treatment options include surgery, radiation, cytotoxic chemotherapy, and multikinase inhibitor therapy. The role of immunotherapy in ATC is an area of active interest and recent evidence suggests that it may be a potentially effective treatment option. Methods: We report a case series of 13 patients with locally advanced or metastatic unresectable ATC who received immune checkpoint inhibitor therapy (pembrolizumab or nivolumab) at a single institution. Results: The patients' median age was 70 years, 54% (7/13) were male, and 85% (11/13) had stage IVC disease with lungs and lymph nodes being the most common sites of metastases. Ten patients had tumor tissue available for programmed death-ligand 1 (PD-L1) expression testing, all of which were positive for PD-L1, and seven of these patients also had a BRAFV600E mutation. The median progression-free survival was 1.9 months and median overall survival (OS) was 4.4 months. The objective response rate was 16% (2/13). Two patients had partial response (PR), and three patients had durable stable disease. Among patients with a clinical benefit, after a median follow-up of 13.5 months, median OS had not been reached (range 4+ to 29+ months). Responses were ongoing in four subjects. The one-year survival rate was 38% (5/13). Six patients (46%) experienced an immune-related adverse event, and 15% (2/13) experienced a grade 3 or higher adverse event, including one patient with grade 5 immune checkpoint-related thyroiditis. Conclusions: Immune checkpoint blockade was well tolerated with a toxicity profile consistent with published literature on PD-1/PD-L1-targeting therapies. For ATC patients, immune checkpoint inhibition may represent an effective treatment option with robust sustained responses seen in a subset of patients." @default.
• W4280579758 created "2022-05-22" @default.
• W4280579758 creator A5021465843 @default.
• W4280579758 creator A5035552610 @default.
• W4280579758 creator A5036473043 @default.
• W4280579758 creator A5042435746 @default.
• W4280579758 creator A5047022703 @default.
• W4280579758 creator A5071104992 @default.
• W4280579758 creator A5084718087 @default.
• W4280579758 creator A5090630599 @default.
• W4280579758 date "2022-08-01" @default.
• W4280579758 modified "2023-10-03" @default.
• W4280579758 title "An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma" @default.
• W4280579758 cites W2572623634 @default.
• W4280579758 cites W2604320765 @default.
• W4280579758 cites W2737933209 @default.
• W4280579758 cites W2744849445 @default.
• W4280579758 cites W2766581537 @default.
• W4280579758 cites W2790254562 @default.
• W4280579758 cites W2832528908 @default.
• W4280579758 cites W2911232639 @default.
• W4280579758 cites W2996574710 @default.
• W4280579758 cites W3021719484 @default.
• W4280579758 cites W3083986479 @default.
• W4280579758 cites W3124581135 @default.
• W4280579758 cites W3137149901 @default.
• W4280579758 cites W3157882994 @default.
• W4280579758 cites W4225157426 @default.
• W4280579758 doi "https://doi.org/10.1089/thy.2022.0073" @default.
• W4280579758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35583228" @default.
• W4280579758 hasPublicationYear "2022" @default.
• W4280579758 type Work @default.
• W4280579758 citedByCount "7" @default.
• W4280579758 countsByYear W42805797582022 @default.
• W4280579758 countsByYear W42805797582023 @default.
• W4280579758 crossrefType "journal-article" @default.
• W4280579758 hasAuthorship W4280579758A5021465843 @default.
• W4280579758 hasAuthorship W4280579758A5035552610 @default.
• W4280579758 hasAuthorship W4280579758A5036473043 @default.
• W4280579758 hasAuthorship W4280579758A5042435746 @default.
• W4280579758 hasAuthorship W4280579758A5047022703 @default.
• W4280579758 hasAuthorship W4280579758A5071104992 @default.
• W4280579758 hasAuthorship W4280579758A5084718087 @default.
• W4280579758 hasAuthorship W4280579758A5090630599 @default.
• W4280579758 hasConcept C121608353 @default.
• W4280579758 hasConcept C126322002 @default.
• W4280579758 hasConcept C141071460 @default.
• W4280579758 hasConcept C143998085 @default.
• W4280579758 hasConcept C197934379 @default.
• W4280579758 hasConcept C2777701055 @default.
• W4280579758 hasConcept C2780030458 @default.
• W4280579758 hasConcept C2780057760 @default.
• W4280579758 hasConcept C71924100 @default.
• W4280579758 hasConcept C90924648 @default.
• W4280579758 hasConceptScore W4280579758C121608353 @default.
• W4280579758 hasConceptScore W4280579758C126322002 @default.
• W4280579758 hasConceptScore W4280579758C141071460 @default.
• W4280579758 hasConceptScore W4280579758C143998085 @default.
• W4280579758 hasConceptScore W4280579758C197934379 @default.
• W4280579758 hasConceptScore W4280579758C2777701055 @default.
• W4280579758 hasConceptScore W4280579758C2780030458 @default.
• W4280579758 hasConceptScore W4280579758C2780057760 @default.
• W4280579758 hasConceptScore W4280579758C71924100 @default.
• W4280579758 hasConceptScore W4280579758C90924648 @default.
• W4280579758 hasIssue "8" @default.
• W4280579758 hasLocation W42805797581 @default.
• W4280579758 hasLocation W42805797582 @default.
• W4280579758 hasOpenAccess W4280579758 @default.
• W4280579758 hasPrimaryLocation W42805797581 @default.
• W4280579758 hasRelatedWork W2342781363 @default.
• W4280579758 hasRelatedWork W2518309888 @default.
• W4280579758 hasRelatedWork W2785808209 @default.
• W4280579758 hasRelatedWork W2969738919 @default.
• W4280579758 hasRelatedWork W2988525911 @default.
• W4280579758 hasRelatedWork W3029766637 @default.
• W4280579758 hasRelatedWork W3043416314 @default.
• W4280579758 hasRelatedWork W3119950328 @default.
• W4280579758 hasRelatedWork W3215044659 @default.
• W4280579758 hasRelatedWork W4221021748 @default.
• W4280579758 hasVolume "32" @default.
• W4280579758 isParatext "false" @default.
• W4280579758 isRetracted "false" @default.
• W4280579758 workType "article" @default.